Search

A clinical trial, NCT06649383, is being conducted to investigate whether Virtual Reality (VR) can be an alternative to traditional medications for alleviating anxiety in elderly patients undergoing surgery under local anesthesia. The trial aims to compare the effects of standard sedation versus sedation/VR on stress levels, pain, and satisfaction of surgeons and nurse anesthetists. The study will involve elderly patients aged 65 or older and will assess various outcomes such as propofol dosage, anxiety-induced stress, and postoperative recovery measures. The trial is set to enroll 90 participants and is scheduled for completion by June 15, 2029. [Extracted from the article]

A clinical trial, NCT06655454, is being conducted to study the effects of supplemental postoperative 0.5% bupivacaine with 1:200,000 epinephrine following non-surgical endodontic treatment on patients' quality of life, pain, and analgesic consumption. The trial aims to compare the impact of an additional injection of long-acting anesthetic to a mock injection group and a group with no additional anesthetic to assess any differences in effects. The study is set to enroll 150 participants and is expected to be completed by September 30, 2025. [Extracted from the article]

A clinical trial, NCT06646731, is being conducted to investigate the use of ultrasound-guided percutaneous cryoneurolysis for treating diabetic neuropathy of the foot. Cryoneurolysis involves freezing the nerve to provide a prolonged nerve block, with minimal discomfort and no systemic side effects. Participants will be randomly assigned to receive cryoneurolysis or a sham procedure, with the primary outcome measure being the change in pain on the neuropathic pain scale one month after the procedure. The study aims to assess the efficacy of cryoneurolysis in improving pain outcomes for individuals with painful diabetic neuropathy. [Extracted from the article]

A clinical trial, NCT06653439, is investigating the analgesic effect of ultrasound-guided bilateral subcostal anterior quadratus lumborum block in laparoscopic colorectal surgery. The study aims to reduce postoperative pain and opioid consumption by utilizing regional anesthesia techniques like the quadratus lumborum block. The trial will assess morphine consumption, pain scores, nausea and vomiting, time of first analgesic request, need for rescue analgesia, and complications in patients undergoing laparoscopic colorectal surgery. The study is not yet recruiting participants and is expected to be completed by April 1, 2025. [Extracted from the article]

A clinical trial comparing the effectiveness of Rhomboid Intercostal Block (RIB) and Retrolaminar Block (RLB) for postoperative analgesia after thoracoscopic sympathectomy in adult patients is underway at Damanhour Teaching Hospital in Egypt. The trial aims to assess the impact of these techniques on patient outcomes, with 60 patients scheduled for elective surgery participating in the study. The primary outcome measures include the time to the first request for postoperative rescue analgesic, Numeric Pain Rating Scale (NPRS) scores, and the total dose of rescue analgesic consumed within 24 hours post-surgery. [Extracted from the article]

A clinical trial, NCT06655025, is being conducted to evaluate the impact of Dexmedetomidine on postoperative cognitive function and serum Neuron Specific Enolase levels in patients undergoing open heart surgery. The trial aims to assess neuronal injury using the Mini-Mental State Examination and serum Enolase levels as indicators. The study is recruiting 32 participants in Egypt and is expected to be completed by October 8, 2025. The trial is focused on evaluating the effects of Dexmedetomidine on cognitive function and neuronal injury in patients undergoing open heart surgeries. [Extracted from the article]

A recent study conducted in Karnataka, India, focused on investigating predictors in the switch from parenteral to oral analgesia in postoperative patients. The study, which involved 305 patients at a tertiary care teaching hospital, found that the switch was mainly done within 2-4 days, with a combination of paracetamol and tramadol being the most common choice. Interestingly, factors such as age, severity of pain, and length of hospital stay were not significantly associated with the switch. The research concluded that while switching between routes of analgesic administration may be effective, the decision to switch does not appear to be influenced by certain hypothesized factors. [Extracted from the article]

A recent study conducted at the University of Nebraska Medical Center focused on developing ProGel-Dex, a thermoresponsive polymeric dexamethasone prodrug for chronic arthritis pain relief. The research aimed to identify formulation parameters that affect the analgesic efficacy of ProGel-Dex, which has shown promising results in providing sustained improvement in pain-related behavior and inflammation in rodent models of arthritis. The study concluded that understanding these formulation parameters is crucial for designing more effective, sustained, and safe relief for joint pain and inflammation in arthritis patients. The research was supported by the National Institutes of Health (NIH) and the China Scholarship Council, and has been peer-reviewed for publication in Nanomedicine Nanotechnology Biology and Medicine. [Extracted from the article]

A study conducted at Chongqing Medical University in China focused on using a convolutional neural network model to analyze electroencephalogram (EEG) signals during anesthesia administration. The study compared the effects of propofol alone versus a combination of propofol and etomidate on consciousness levels in surgery patients. The research found that the 1D CNN model was effective in assessing the depth of anesthesia based on EEG features, providing valuable insights for anesthesiologists. The study highlighted the importance of using EEG indicators to monitor consciousness and adjust anesthesia dosages accordingly. [Extracted from the article]

Researchers at the Catholic University of Korea conducted a meta-analysis to evaluate the efficacy of topically applied tramadol in the peritonsillar area for pain control in children undergoing adenotonsillectomy. The study found that tramadol significantly reduced postoperative pain and the time to take the first pain-reducing drugs compared to a placebo. However, tramadol showed no significant difference in pain relief compared to other topical agents. The research concluded that tramadol's efficacy in pain control was similar to other agents in pediatric adenotonsillectomy. [Extracted from the article]

A recent report from the University Health Network in Toronto, Canada, discusses perioperative approaches to prevent delayed neurocognitive recovery (DNR) and postoperative neurocognitive disorder (P-NCD) in older noncardiac surgical patients. The study included 39 randomized controlled trials (RCTs) involving anesthetic and other pharmacological and nonpharmacological interventions. The meta-analysis revealed that perioperative dexmedetomidine and propofol-based total intravenous anesthesia (TIVA) significantly decreased the risk of DNR in older patients undergoing noncardiac surgery, while regional anesthesia (RA) and bispectral index (BIS) monitoring did not show significant effects. Further research on the effects of interventions on DNR and P-NCD is recommended. [Extracted from the article]

A recent study conducted by the Ministry of Health of Russia focused on orofacial pain in oncology and the use of a new analgesic peptide called tafalgin. The research highlighted the prevalence of severe pain in patients with head and neck tumors and the importance of managing pain throughout different stages of cancer treatment. The study concluded that tafalgin, a peptide analgesic, showed promising results in providing relief and could be considered as an alternative to traditional opioid analgesics. For more information, the full article can be accessed through the provided link. [Extracted from the article]

A recent study conducted at PGIMS in Haryana, India, evaluated the analgesic efficacy of a 5% lidocaine patch in patients with post-herpetic neuralgia (PHN). The study included 24 patients with PHN, and results showed a significant reduction in pain scores over four weeks of treatment with the lidocaine patch. The researchers concluded that the 5% lidocaine patch is an effective and well-tolerated treatment for moderate to severe pain associated with PHN. [Extracted from the article]

A recent study published in Pain & Central Nervous System Week explores the use of berberine and berberine nanoparticles in mitigating scopolamine-induced amnesia in rats. The research involved administering different treatments to male Wistar rats and analyzing their biochemical responses. The results indicated significant differences in plasma and brain parameters among the experimental groups, with berberine nanoparticles showing promise in increasing brain protein levels and improving brain uric acid levels. For more information, the full article can be accessed for free at https://doi.org/10.1093/ajcp/aqae129.048. [Extracted from the article]

Recent research from the University of Findlay highlights the impact of over-the-counter analgesic-related exposure and toxicity in pediatric patients in Ohio. The study focused on the toxicities arising from the use of OTC analgesic medications in different age groups, with findings showing that unintentional exposure was a common cause of toxicity, particularly in younger children. The research underscores the importance of raising awareness about OTC analgesic toxicities, which remain prominent in Ohio. [Extracted from the article]

A study conducted at Cairo University focused on the impact of Helicobacter pylori eradication on the serum level of valproic acid in children with idiopathic generalized epilepsy. The research involved 100 children with epilepsy and found that eradication of H. pylori led to a significant increase in serum VPA levels and a decrease in epileptic attacks per month. The study suggests that H. pylori screening for children with epilepsy could optimize serum VPA levels and potentially improve seizure control. [Extracted from the article]

A study conducted at Lithuanian University of Health Sciences explored the effects of anesthesia with pentobarbital/ketamine on mitochondrial permeability transition pore opening and ischemic brain damage. The research found that pentobarbital/ketamine anesthesia delayed mPTP opening, improved mitochondrial respiratory functions, and reduced cell death in rat brain slices. The study suggests that modulation of mitochondrial complex I activity by pentobarbital during anesthesia may increase mitochondrial resistance to mPTP opening, a key event in brain cell necrosis during ischemia. For more information, the full article can be accessed for free at the Biomedicines journal website. [Extracted from the article]

A study conducted at Indira Gandhi Government Medical College examined the efficacy of ondansetron and granisetron in preventing post-operative shivering in patients receiving general anesthesia. The research found that granisetron was more effective than ondansetron in preventing shivering post-operatively without affecting the patients' hemodynamic state. This study highlights the potential benefits of using 5-HT3 receptor blockers as premedication for patients undergoing laparoscopic surgeries. For more information, readers can refer to the Indian Journal of Applied Research. [Extracted from the article]

A recent study from Johns Hopkins University focused on the use of the antiseizure medication Levetiracetam (LEV) in pregnant women with epilepsy (WWE). The research aimed to characterize changes in LEV clearance during pregnancy and the postpartum period to optimize dosing for pregnant women. The study observed a decrease in LEV concentration/dose during pregnancy, followed by an increase postpartum, highlighting the importance of monitoring LEV levels in WWE before, during, and after pregnancy. This data contributes to establishing a rational treatment and dosing plan for LEV use in pregnant women with epilepsy. [Extracted from the article]

A recent study conducted by the Department of Psychiatry in Charlotte, North Carolina, focused on the effectiveness of non-opioid psychiatric medications in managing chronic pain, particularly in patients with psychiatric comorbidities. The study analyzed various medications such as duloxetine, mirogabalin, pregabalin, gabapentin, and tricyclic antidepressants across different chronic pain conditions like fibromyalgia, neuropathic pain, and chronic low back pain. While some medications showed significant short-term efficacy in fibromyalgia patients, the overall long-term benefits of these drugs in chronic pain management were inconclusive, emphasizing the need for further research in this area. [Extracted from the article]

A study conducted by Seoul National University School of Dentistry in South Korea found that the antipsychotic chlorpromazine can reduce neuroinflammation by inhibiting microglial voltage-gated potassium channels. The research suggests that chlorpromazine acts as a microglial Kv1.3 channel inhibitor and neuroinflammation modulator, potentially offering therapeutic benefits for neuroinflammatory psychiatric and neurological disorders. The study was supported by the National Research Foundation of Korea and has been peer-reviewed, providing valuable insights into the potential mechanisms of action for chlorpromazine in treating neuroinflammation. [Extracted from the article]

A recent report from Uppsala University in Sweden discusses the increasing number of clinical trials involving ketamine and its enantiomer, esketamine, for various indications. The FDA has approved esketamine for treatment-resistant depression, while ketamine is used for anesthesia and pain management. The research suggests that the number of studies on ketamine will continue to grow, potentially leading to approval for additional indications in the future. [Extracted from the article]

A study conducted by the University of Calgary analyzed trends in analgesia use for children with sickle cell disease and vaso-occlusive pain episodes over an 11-year period in U.S. pediatric emergency departments. The research found an increased use of NSAIDs, ketamine, and acetaminophen, with consistent opioid use. Larger hospitals were more likely to administer opioids but less likely to co-administer NSAIDs with opioids compared to medium-volume hospitals. The study concluded that variations in analgesia practices across hospitals highlight the importance of standardizing pain management strategies for this population. [Extracted from the article]

A study conducted by Geneva University Hospitals evaluated the economic impact of the PedAMINES app in reducing medication errors in pediatric emergency care. The app automates dose calculations for drugs like epinephrine, norepinephrine, dopamine, and midazolam, aiming to prevent adverse drug events. The research found that the app could potentially reduce errors and be cost-effective, with the primary factors influencing cost per error being app maintenance, likelihood of adverse events, and underdosing frequency. The study advocates for widespread adoption of the app to benefit pediatric emergency care in Switzerland. [Extracted from the article]

A recent study conducted at the Hospital for Sick Children in Toronto, Canada, explored the use of acetazolamide as a therapeutic alternative for central sleep apnea in pediatric patients with an FBXO28 gene mutation. The research found that acetazolamide, a carbonic anhydrase inhibitor, may help stabilize respiratory disturbances by enhancing ventilatory drive in children with neurodevelopmental disorders and genetic syndromes. The study highlighted the potential benefits of acetazolamide in improving the quality of life for pediatric patients with central sleep apnea, while emphasizing the need for further research to establish standardized treatment protocols and ensure long-term safety. [Extracted from the article]

The University of Pennsylvania conducted research on barriers and facilitators to implementing CareConnect, a telehealth, low-barrier buprenorphine bridge clinic in Philadelphia. The study aimed to increase access to buprenorphine for individuals with opioid use disorder who face care access barriers. Findings highlighted the importance of innovative delivery models and buy-in from outside stakeholders for the program's effectiveness. The research provides valuable insights to improve and sustain CareConnect and guide the development of similar programs nationally. [Extracted from the article]

A recent study conducted by researchers at the University of South Florida analyzed data from the FDA Adverse Event Reporting System (FAERS) to investigate the relationship between triptans (sumatriptan, rizatriptan, and zolmitriptan) and cardiovascular adverse events in migraine treatment. The study found that women reported more cardiovascular adverse events with rizatriptan and zolmitriptan compared to men, and individuals aged 18-64 had the highest risk. Sumatriptan was associated with a higher cardiovascular risk than rizatriptan and zolmitriptan, with most deaths and serious cases documented for sumatriptan. This research may help in evaluating the risk of triptan treatment for migraines. [Extracted from the article]